Ovarian cancer immunotherapy: opportunities, progresses and challenges
about
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesisHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesImmunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancerHuman tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.The effect of sortilin silencing on ovarian carcinoma cells.Altered protein expression in serum from endometrial hyperplasia and carcinoma patients.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Production and Characterization of a Novel Monoclonal Antibody Against Human SortilinImmunotherapy in ovarian cancer.Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor InfiltrationIL‑6 and IL‑8 enhance factor H binding to the cell membranes.Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.Peritoneal immune system in patients with advance epithelial ovarian cancer.Current management and novel agents for malignant melanoma.Dendritic cell immunotherapy in ovarian cancer.Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.Cancer immunotherapy: are we there yet?Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas.Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkersPotential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.The immunopeptidomic landscape of ovarian carcinomas.Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.
P2860
Q26822545-D184EC20-78F5-45E5-8A5F-E1E4000656D7Q26822730-AB240E3F-2AD6-4993-BC60-868834972122Q33357295-069F74B9-E3A1-49E2-B7E2-4BBAAD9C613CQ33565624-D0A9B3F0-426A-4427-90EF-069AC32CF98FQ33942459-5DE117C9-A054-44AA-A456-A2C6C45225C1Q34016504-8A30CCFA-A28B-45C6-8FD3-4F3431CCE00CQ34099990-BC8B2A31-8C51-4B8E-8A39-3FDD07989E35Q34989853-C956A746-58D7-4524-BE63-D2FB122C21B7Q35088311-5EBD62E9-E7E8-49DE-AAE5-35F405B39515Q36388428-BFF16A44-6DC5-44E1-B43B-FCE6480215C2Q36631249-00288BFA-E4A5-4C70-809A-263847436831Q36711835-B58392E6-F01C-40F2-AF20-300B8A661AA8Q36817388-399D764F-E02C-4933-BAAD-F62AFF515C53Q36949580-6B18613A-0BC2-4DB0-9B20-092BE37FDA26Q37459636-482B6163-6728-4499-8417-7E57704D488EQ37521291-504F4F74-163E-4682-AAEA-04EA2E7C66F4Q37873925-2C3C81DF-681C-4560-9929-EF8F87ABAFD6Q37983934-91EC2421-CF44-4FAA-A40C-97436020F1A3Q38069183-8CD5244C-4415-4F3F-BB41-DBF0385662CCQ38721999-8D070AAA-B7B9-4AD5-9AA0-EED8D127A934Q39297560-FD09188C-D9C6-46F0-9BE6-0CE7F5E0B521Q41137180-4CEE1418-145B-4297-B56E-ADFF3A9B9774Q42153370-B3D8BBAB-4F0C-4CBF-9B10-236C51ECACDCQ42378844-B95939DE-C413-4E13-8D2C-A4F98B2249E5Q46708524-E58807CC-DE6A-4AB7-918A-69B3C7C1B103Q47096103-2A55A545-DD5B-4B62-AF21-82AA6973C068Q50696151-011E5EA9-3917-4C66-903A-96B130ED4CBCQ55297626-EA4AEE62-4C1A-4C83-A80C-83C7040F6A1A
P2860
Ovarian cancer immunotherapy: opportunities, progresses and challenges
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@ast
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@en
type
label
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@ast
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@en
prefLabel
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@ast
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@en
P2093
P2860
P921
P356
P1476
Ovarian cancer immunotherapy: opportunities, progresses and challenges
@en
P2093
Carolyn Runowicz
Helen Swede
Richard Stevens
P2860
P2888
P356
10.1186/1756-8722-3-7
P5008
P577
2010-02-10T00:00:00Z
P5875
P6179
1007858872